Ibuprofen and Antibiotic Co-Delivery via Nanoparticles: A Novel Approach to Treating Pseudomonas aeruginosa Infections in Cystic Fibrosis - A Protocol Study

Abstract

Introduction: Cystic fibrosis (CF) is a genetic disorder that severely affects the lungs, leading to chronic infections primarily by Pseudomonas aeruginosa (P. aeruginosa). This pathogen adapts to the CF lung environment, forming biofilms that contribute to persistent infections and antibiotic resistance. ibuprofen, a non-steroidal anti-inflammatory drug, has shown potential in disrupting biofilms and enhancing antibiotic efficacy against P. aeruginosa. Recent studies focus on delivering ibuprofen via nebulization, using nanoparticles to improve targeting and reduce drug dosage.

Methods: This paper explores the in vitro and in vivo effects of nebulized ibuprofen nanoparticles combined with the antibiotic ceftazidime. The study hypothesizes that this co-delivery system can reduce bacterial load, inflammation, and biofilm formation more effectively than standard treatments.

Results: Results are anticipated to show that ibuprofen enhances antibiotic penetration and disrupts biofilm structure, thereby improving therapeutic outcomes in CF patients.

Discussion: This research suggests a promising direction for CF treatment, leveraging advanced drug delivery systems to combat bacterial resistance and improve patient prognosis.